BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15131029)

  • 1. Dendritic cell vaccination in medullary thyroid carcinoma.
    Stift A; Sachet M; Yagubian R; Bittermann C; Dubsky P; Brostjan C; Pfragner R; Niederle B; Jakesz R; Gnant M; Friedl J
    Clin Cancer Res; 2004 May; 10(9):2944-53. PubMed ID: 15131029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma.
    Bachleitner-Hofmann T; Friedl J; Hassler M; Hayden H; Dubsky P; Sachet M; Rieder E; Pfragner R; Brostjan C; Riss S; Niederle B; Gnant M; Stift A
    Oncol Rep; 2009 Jun; 21(6):1585-92. PubMed ID: 19424640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medullary thyroid carcinoma: autologous tumor cell lines for dendritic cell vaccination.
    Pfragner R; Skofitsch G; Höger H; Jech M; Rinner B; Siegl V; Niederle B; Gnant M; Friedl J; Stift A
    Anticancer Res; 2005; 25(6B):4225-30. PubMed ID: 16309220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination.
    Schott M; Seissler J; Lettmann M; Fouxon V; Scherbaum WA; Feldkamp J
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4965-9. PubMed ID: 11600571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma.
    Papewalis C; Wuttke M; Jacobs B; Domberg J; Willenberg H; Baehring T; Cupisti K; Raffel A; Chao L; Fenk R; Seissler J; Scherbaum WA; Schott M
    Horm Metab Res; 2008 Feb; 40(2):108-16. PubMed ID: 18283628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell-based vaccination in solid cancer.
    Stift A; Friedl J; Dubsky P; Bachleitner-Hofmann T; Schueller G; Zontsich T; Benkoe T; Radelbauer K; Brostjan C; Jakesz R; Gnant M
    J Clin Oncol; 2003 Jan; 21(1):135-42. PubMed ID: 12506182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells.
    Stift A; Friedl J; Dubsky P; Bachleitner-Hofmann T; Benkoe T; Brostjan C; Jakesz R; Gnant M
    Int J Oncol; 2003 Mar; 22(3):651-6. PubMed ID: 12579320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat shock treatment of tumor lysate-pulsed dendritic cells enhances their capacity to elicit antitumor T cell responses against medullary thyroid carcinoma.
    Bachleitner-Hofmann T; Strohschneider M; Krieger P; Sachet M; Dubsky P; Hayden H; Schoppmann SF; Pfragner R; Gnant M; Friedl J; Stift A
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4571-7. PubMed ID: 16954161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer.
    Chang AE; Redman BG; Whitfield JR; Nickoloff BJ; Braun TM; Lee PP; Geiger JD; Mulé JJ
    Clin Cancer Res; 2002 Apr; 8(4):1021-32. PubMed ID: 11948109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study.
    Babatz J; Röllig C; Oelschlägel U; Zhao S; Ehninger G; Schmitz M; Bornhäuser M
    J Hematother Stem Cell Res; 2003 Oct; 12(5):515-23. PubMed ID: 14594508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen.
    Itoh T; Ueda Y; Kawashima I; Nukaya I; Fujiwara H; Fuji N; Yamashita T; Yoshimura T; Okugawa K; Iwasaki T; Ideno M; Takesako K; Mitsuhashi M; Orita K; Yamagishi H
    Cancer Immunol Immunother; 2002 Apr; 51(2):99-106. PubMed ID: 11904734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinoma using tumor lysate-pulsed dendritic cells.
    Bachleitner-Hofmann T; Stift A; Friedl J; Pfragner R; Radelbauer K; Dubsky P; Schüller G; Benkö T; Niederle B; Brostjan C; Jakesz R; Gnant M
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1098-104. PubMed ID: 11889172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides.
    Liu KJ; Wang CC; Chen LT; Cheng AL; Lin DT; Wu YC; Yu WL; Hung YM; Yang HY; Juang SH; Whang-Peng J
    Clin Cancer Res; 2004 Apr; 10(8):2645-51. PubMed ID: 15102666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
    Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ
    Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFN-alpha skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo.
    Papewalis C; Jacobs B; Wuttke M; Ullrich E; Baehring T; Fenk R; Willenberg HS; Schinner S; Cohnen M; Seissler J; Zacharowski K; Scherbaum WA; Schott M
    J Immunol; 2008 Feb; 180(3):1462-70. PubMed ID: 18209041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells.
    Babatz J; Röllig C; Löbel B; Folprecht G; Haack M; Günther H; Köhne CH; Ehninger G; Schmitz M; Bornhäuser M
    Cancer Immunol Immunother; 2006 Mar; 55(3):268-76. PubMed ID: 16034561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.
    Lesterhuis WJ; De Vries IJ; Schreibelt G; Schuurhuis DH; Aarntzen EH; De Boer A; Scharenborg NM; Van De Rakt M; Hesselink EJ; Figdor CG; Adema GJ; Punt CJ
    Anticancer Res; 2010 Dec; 30(12):5091-7. PubMed ID: 21187495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors.
    Tamir A; Basagila E; Kagahzian A; Jiao L; Jensen S; Nicholls J; Tate P; Stamp G; Farzaneh F; Harrison P; Stauss H; George AJ; Habib N; Lechler RI; Lombardi G
    Cancer Immunol Immunother; 2007 Dec; 56(12):2003-16. PubMed ID: 17333181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.